Introduction
Oligohydramnios refers to an amniotic fluid index (AFI) less than the fifth percentile expected for the gestational age, and AFI 5 cm is used as a cutoff for diagnosis [1] . It complicates 3-5% of pregnancies, and in less than 50% of the cases, the diagnosis is confirmed without fetal-maternal etiologic risk factors and is so-called ''isolated oligohydramnios" (IO) [2] .
Promising evidence proposes that IO at a term is a weak marker of perinatal outcome. In term pregnancies induction of labor would be reasonable [3] , however; conservative management with strict follow-up should be a gold standard in a preterm IO [4] .
The pathophysiological explanation of IO is not clearly understood, however; it has been deemed a sign that reflects chronic or late-onset impairment of placental function [5] .
Several medical modalities have been attempted to treat oligohydramnios. Although short-term improvement in AFI is satisfactory, the long-term effect is questionable.
Isosorbide mononitrate (IMN) is an in vivo NO donor and is used in several obstetric indications. Endothelial nitric oxide (eNO) synthesized by nitric oxide synthases (NOS) from the precursor, Larginine, is the chief regulator of fetal-placental perfusion. Nitric oxide induces vasodilatation and inhibits platelet aggregation. These mechanisms improve uteroplacental perfusion as; they augment the volume and reduce the viscosity of blood in the fetomaternal circulation [6, 7] .
The purpose of this work was to compare Isosorbide mononitrate (IMN) plus oral hydration therapy with oral hydration alone in increasing the AFI in pregnancies complicated by isolated oligohydramnios and to assess related pregnancy outcomes.
Materials and methods
This randomized controlled trial was approved by the Local Ethics Committee of Obstetrics and Gynecology Department, Benha University Hospital, and registered at Clinical Trials.gov: NCT02712125. Participants were recruited among those attending the antenatal care clinic of Benha University Hospital, from August 2013 to April 2017. Participants had a singleton pregnancy, at 28-36 weeks gestation, with unexplained oligohydramnios (AFI < 5 cm). Pregnant women with oligohydramnios associated with intrauterine growth restriction, fetal congenital anomalies, nonreassuring Non Stress Test (NST) or abnormal fetal Doppler indices, rupture of membranes, active labor, preexisting chronic medical problems (e.g., hypertension, severe hypotension, pregestational diabetes, lung, heart, kidney disease, or closed angle glaucoma), pregnant treated with vasodilator or antiprostaglandins, sensitive or had contraindications to NO donors were all the exclusion criteria. All participants gave written informed consent and had the right to be withdrawn from the study at any time.
Participants were randomly allocated to one of two equal groups by a computer-generated random number table. The study group received oral hydration pulse 20 mg isosorbide mononitrate (IMN) (Effox, Mina Pharma Co, Egypt; under license of Schwartz Pharma, Germany) vaginally once daily and the control group received oral hydration plus placebo vaginal tablet once daily. Group allocation was concealed for both participant and doctor by using numbered opaque sealed envelopes, opened in sequence by a third person (study nurse). Participants were ordered to drink 2 L of water or fruit juice within two hours plus the daily water requirement. Patients were advised to rest in the left lateral position after oral hydration. Drug treatment continued until the AFI reached the normal value or until delivery. Hospital admission was considered for at least 24 h, and participants were followed for any maternal or fetal adverse outcomes. All participants had ultrasonographic examination 24 h after receiving treatment to reassess AFI. Women with at least 20% increase in AFI were discharged. The amniotic fluid index was estimated using the standard technique described by Phelan et al. [8] using an abdominal convex probe of 3.5 MHz (Voluson, 730 Pro V, GE Medical System), by a single Ultrasonographer to avoid interobserver variability. The mean of two AFI measures was recorded.
Participants continued antenatal vitamins. A single course of intramuscular Dexamethasone in a total dose of 24 mg (6 mg/12 h) was given to any pregnant less than 34 completed weeks of gestation to promote fetal lung maturity.
Patient's follow-up included, AFI, biophysical profile, and fetal Doppler once weekly and NST twice weekly till delivery. Participants were readmitted to hospital with any maternal or fetal adverse events. The primary outcome measure was the change in AFI. Secondary outcomes were treatment onset to delivery interval, gestational age at birth, indications, and mode of delivery and neonatal outcome regards birth weight, stillbirth or neonatal death, 5-min Apgar score and the need for neonatal admission and the side-effects of isosorbide mononitrate if any.
Sample size calculation
A previous randomized study [9] showed a 32.3% increase in the mean AFI following maternal oral hydration in cases of oligohydramnios. We presumed a 20% increase in the AFI in combined IMN and hydration group would be of clinical significance. Consequently; each group required 95 participants to give the study, 80% power at a confidence interval of 95% using a two-tailed chi-square test with a 0.05 significance level (type a error). The sample size was increased to 105 participants in each group after assuming a dropout incidence of 10%.
Statistical analysis
The collected data were statistically analyzed using SPSS version 15.0. Qualitative data were expressed as numbers and percentages and the differences were tested using Fisher exact test or the Chi-square test as appropriate. Quantitative data were expressed as mean ± SD, and/or median (minimum-maximum). Means were compared using the unpaired or paired Student's ttest as appropriate. Odds ratio with 95% confidence interval (CI) were calculated for Qualitative data when possible. The statistical significance was considered at a p-value level <0.05.
Results
Fig . 1 shows the flow of participants during the study. Table 1 shows no significant differences between the basic characteristics of the study and control groups. Table 2 shows a significant increase of AFI in both groups detected from 24 h up to one week after treatment. The amniotic fluid volume (AFV) was higher in the IMN group at the final estimation (10.659 ± 0.61 compared with 5.333 ± 1.434 cm, P < 0.001). The incidence of participants continued undelivered was significantly higher for those assigned to IMN/Hydration from the 3rd week following treatment onward (P = 0.0015). Table 3 shows significantly better maternal, fetal and neonatal outcomes in the IMN-hydration group compared to hydration only group. Neonatal deaths were reported in one case of the study group and 5 in the control group, and the difference was not significant. A headache, palpitations, and hypotension, the commonest side effects in the study, were significantly higher in IMN-hydration group compared to the hydration-only group. These were mild, tolerable, and did not require a stoppage of therapy.
Discussion
The current study shows a significant increase of AFI following maternal oral hydration in pregnancies complicated by IO. These findings agree with, Gizzo et al. [4] in their systematic review and meta-analysis, reporting the simplicity and effectiveness of maternal oral hydration compared to intravenous hydration for increasing amniotic fluid volume (AFV) in cases of IO, and superiority of hypotonic solutions to isotonic solutions. Unfortunately; these effects are short-lived, reported being less than 24 h [10] up to one-week [11] . In the current study, the improvement of AFI was not continued after the 1st week of hydration unless IMN was added that was not fully understood. We suggest that this time-limited effect of hydration only regimen was attributed to increasing intramembranous absorption and fetal swallowing that act as countercurrent mechanisms of increased amniotic fluid, start to function shortly after improvement of AFI [12] .
The favorable effect of IMN in AFI was suspected to be through the increase in the fetal urine output, the main source of amniotic fluid in the second half of pregnancy. Isosorbide mononitrate induces vascular relaxation, improves microcirculation via inhibition of platelet aggregation. Consequently, it increases uteroplacental perfusion, fetal renal blood flow with subsequent increase in fetal urine production. The reported improvement in the AFI with IMN was in line with other studies evaluating other NO agents; NO precursors (L-arginine) and NO mediator (Sildenafil citrate) in the treatment of idiopathic oligohydramnios and preeclampsia or intrauterine growth restriction associated oligohydramnios [13, 14] .
The results of the current trial show better pregnancy outcomes in cases treated with IMN plus hydration compared to hydration alone. Antepartum variable deceleration was the commonest abnormality in the hydration only group due to cord compression, was the main indication of cesarean deliveries. However; vaginal birth was significantly higher in IMN-hydration group that may be attributed to successful induction of labor due to the cervical ripening effect of IMN. The current study shows statistically significant low Apgar score, birth weight and statistically significant higher admission to neonatal intensive care units (NICU) with increase period of NICU stay in hydration only group compared to IMN-hydration group. These findings may be attributed to a higher rate of preterm deliveries in the hydration only group secondary to the waning of the transient improvement of AFI. These findings agree with Sherm et al. [15] found that the rates of labor induction, cesarean deliveries, and short-term neonatal morbidity are significantly higher in term pregnancies complicated by IO. Rossi and Prefumo, [3] reported a higher risk of obstetric intervention in term and post-term pregnancies complicated by IO, however; perinatal outcomes are comparable to those of pregnancies with normal AFV. The promising effect of IMN-oral hydration on maternal and perinatal outcomes agrees with Maher et al. [14] reported promising results when comparing Sildenafil -hydration therapy with hydration alone in the third trimester IO. The discrepancy between our results and what was reported by other authors may be attributed to; (1) heterogeneity in patient characteristics, diagnostic criteria, hydration strategies, and outcome measures, (2) our patients included a group of pregnancies remote from the term, and (3) oligohydramnios in such low-risk pregnancies was presumed to be a marker of delayed onset suboptimal placental perfusion, therefore; perinatal outcomes improved markedly by adding IMN.
Isosorbide Mononitrate is classified as FDA pregnancy risk category B as no fetal toxic effects have been reported in experimental animal studies, however; human studies are inadequate. Therefore, its use during a pregnancy should be limited to proper indications [16] . Headache, palpitations, and hypotension are the commonest side effects reported with the IMN use in the current study. These side effects are mild and did not need a stoppage of treatment. , kilogram per squared meter; IMN, isosorbide mononitrate; n (%)}, number (percent). Data presented as, number (percent), median (minimum-maximum) or mean ± standard deviation. Table 2 The changes in the amniotic fluid index in both groups throughout the study. Bullarbo et al. [17] agree, however; Hatanaka et al. [18] disagree with these findings regarding their studies evaluating IMN use for cervical ripening at the term. The mild severity of IMN sideeffects in the current study may be attributed to the vaginal route of administration whereby; the drug is a subject to the first uterine pass effect, the uterine concentration of the drug is high, however; the serum level is low with delay reaching to the peak concentration [19] . The effect of the drug is related to the local uterine concentration, however; the side effects are related to serum level.
The strengths of the current study include; (1) randomized, (2) double-blinded, (3) placebo was used in the control group, (4) the first study to use NO donors vaginally as a conservative therapy for IO, (5) maternal rest in the left lateral position was standardized during hydration, therefore; the improving effect of this factor in AFV was equalized in all patients, and (6) a wide range of gestational ages (more than 28 weeks) were studied with long-term follow-up and assessment of AFI improvement and pregnancy outcome. The limitations of the current study include; (1) response to therapy was evaluated by a subjective method (AFI) rather than the estimation of definite AFV, (2) treatment compliance was not evaluated, and (3) no postnatal assessment of the newborn for anomalies as oligohydramnios may seem to be unexplained at diagnosis, however; it may be a warning of an anomaly not revealed until delivery.
Conclusion
Isosorbide Mononitrate may offer a promising choice in improving amniotic fluid volume and pregnancy outcomes in pregnancies complicated by isolated oligohydramnios. CTG, cardiotocography; NICU, neonatal intensive care unit; IUFD, intrauterine fetal death; OR, odds ratio; CI, confidence interval. Data presented as number (%), median (minimum-maximum) or mean ± standard deviation.
